From Global Insights to National Impact: Advancing Cardio-Oncology in Iraq
DOI:
https://doi.org/10.32007/jfacmedbaghdad.6643034Keywords:
Cardio-OncologyAbstract
Cancer remains a leading cause of mortality and morbidity worldwide. Advances in cancer therapies—including immunotherapies (e.g., checkpoint inhibitors, gene-targeted therapies), antibody-based cancer toxins, chemotherapy, radiotherapy, and surgery—have significantly improved survival rates 1,2. However, this progress has led to a surge in the prevalence of cardiovascular disease (CVD) among cancer survivors, now recognised as a leading cause of mortality in this population 3,4. These intersecting burdens highlight the growing need to prevent, detect, and manage cardiovascular complications in cancer care pathways and call for important initiatives in establishing cardio-oncology services globally.
Downloads
References
1. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. 2016 Jul 1; 25(7): 1029-36. https://doi.org/10.1158/1055-9965.EPI-16-0133.
2. Cleary S, Rosen SD, Gilbert DC, Langley RE. Cardiovascular health: an important component of cancer survivorship. 2023 [cited 2024 May 24];2(1). https://doi.org/10.1136/bmjonc-2023-000090
3. Lyon AR, Dent S, Stanway S, Earl H, Brezden‐Masley C, Cohen‐Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler‐Klein J, Khoo V. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C ardio‐O ncology S tudy G roup of the H eart F ailure A ssociation of the E uropean S ociety of C ardiology in collaboration with the I nternational C ardio‐O ncology S ociety. European journal of heart failure. 2020 Nov;22(11):1945-60. https://doi.org/10.1002/ejhf.1920.
4. Lamberg M, Rossman A, Bennett A, Painter S, Goodman R, MacLeod J, et al. Next Generation Risk Markers in Preventive Cardio-oncology. 2022 Jun 1 [cited 2024 May 24]; 24(6):443-56. https://doi.org/10.1007/s11883-022-01021-x.
5. Imran S, Rao MS, Shah MH, Gaur A, Guernaoui A El, Roy S, et al. Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives. Vol. 49, Current Problems in Cardiology. Elsevier Inc.; 2024. https://doi.org/10.1016/j.cpcardiol.2024.102389
6. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. Vol. 70, Journal of the American College of Cardiology. Elsevier USA; 2017. p. 2536-51. https://doi.org/10.1016/j.jacc.2017.09.1096.
7. Barac A, Murtagh G, Carver JR, Hui Chen M, Freeman AM, Herrmann J, et al. THE PRESENT AND FUTURE COUNCIL CLINICAL PERSPECTIVES Cardiovascular Health of Patients With Cancer and Cancer Survivors A Roadmap to the Next Level. 2015. https://doi.org/10.1016/j.jacc.2015.04.059.
8. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology. 2020 Aug;17(8):474-502. https://doi.org/10.1038/s41569-020-0348-1.
9. Mauro AG, Hunter K, Salloum FN. Cardiac complications of cancer therapies. In: Advances in Cancer Research. Academic Press Inc.; 2022; 167-214. https://doi.org/10.1016/bs.acr.2022.03.006.
10. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal-Cardiovascular Imaging. 2022 Oct 1;23(10):e333-465. https://doi.org/10.1093/ehjci/jeac106
11. Sparano JA, Sahni G. The ESC Cardio-Oncology Guidelines: A Roadmap for Clinical Practice and Generating Needed Evidence. Vol. 5, JACC: CardioOncology. Elsevier Inc.; 2023; 5(1):141-4. https://doi.org/10.1016/j.jaccao.2022.10.010.
12. Moslehi JJ. Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation. Circulation. 2024 Aug 13;150(7):513-5. https://doi.org/10.1161/CIRCULATIONAHA.124.065473.
13. Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, Wei L, Jneid H, Addison D. Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation. 2019 May 28;139(22): 2594-6. https://doi.org/10.1161/CIRCULATIONAHA.118.039180.
14. Ohtsu H, Shimomura A, Sase K. Real-world evidence in cardio-oncology: What is it and what can it tell us?. Cardio Oncology. 2022 Mar 1; 4(1): 95-7. https://doi.org/10.1016/j.jaccao.2022.02.002.
15. Dafaalla M, Costa F, Kontopantelis E, Araya M, Kinnaird T, Micari A, Jia H, Mintz GS, Mamas MA. Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score. European Heart Journal. 2024 Sep 7;45(34):3138-48. https://doi.org/10.1093/eurheartj/ehae463.
16. Bashar H, Kobo O, Curzen N, Mamas MA. Association of myocardial injury with adverse long-term survival among cancer patients. EJPC. 2024 Mar 21:zwae116. https://doi.org/10.1093/eurjpc/zwae116.
17. Yong JH, Mai AS, Matetić A, Elbadawi A, Elgendy IY, Lopez-Fernandez T, Mamas MA. Cardiovascular Risk in Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis. AJC. 2024 Feb 1;212:80-102. https://doi.org/10.1016/j.amjcard.2023.11.039.
18. Kobo O, Abramov D, Fiuza M, Chew NW, Ng CH, Parwani P, Menezes MN, Thavendiranathan P, Mamas MA. Cardiovascular health metrics differ between individuals with and without cancer. JAHA. 2023 Dec 5;12(23):e030942. https://doi.org/10.1161/JAHA.123.030942.
19. Mohamed MO, Ghosh AK, Banerjee A, Mamas M. Socioeconomic and ethnic disparities in the process of care and outcomes among cancer patients with acute coronary syndrome. Canadian Journal of Cardiology. 2024 Jun 1;40(6):1146-53. https://doi.org/10.1016/j.cjca.2024.03.012.
20. Dafaalla M, Abramov D, Van Spall HG, Ghosh AK, Gale CP, Zaman S, Rashid M, Mamas MA. Heart failure readmission in patients with ST-segment elevation myocardial infarction and active cancer. Cardio Oncology. 2024 Feb 1;6(1):117-29. https://doi.org/10.1016/j.jaccao.2023.10.011.
21. Kobo O, Michos ED, Roguin A, Bagur R, Gulati M, Mamas MA. Recommended and observed statin use among US adults with and without cancer. EJPC. 2024 Feb 9:zwae057. https://doi.org/10.1093/eurjpc/zwae057.
22. Istanbuly S, Matetić A, Bang V, Sharma K, Golwala H, Kheiri B, Osman M, Swamy P, Bharadwaj A, Mamas M. Outcomes of 1.3 million patients undergoing percutaneous coronary intervention according to the presence of cancer and atrial fibrillation: a retrospective study. CMJ. 2024 Oct;65(5):405. https://doi.org/10.3325/cmj.2024.65.405.
23. Farhan HA, Yaseen IF. Perceptions of the Cardiologists and Oncologists: Initial Step for Establishing Cardio-Oncology Service. Front Cardiovasc Med [Internet]. 2021 Nov 24; 8. https://doi.org/10.3389/fcvm.2021.704029.
24. Yaseen IF, Farhan HA. ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology? Eur Heart J [Internet]. 2023 Mar 14;44(11):912-5. https://doi.org/10.1093/eurheartj/ehac701.
25. Yaseen IF, Farhan HA. Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study. Front Cardiovasc Med [Internet]. 2022 Sep 29;9. https://doi.org/10.3389/fcvm.2022.972455.
26. Farhan HA, Yaseen IF, Alomar M, Lenihan D, Dent S, Lyon AR. Global pattern of cardiovascular disease management in patients with cancer and impact of COVID-19 on drug selection: IRAQ-IC-OS survey-based study. Front Cardiovasc Med [Internet]. 2022 Sep 21; 9. https://doi.org/10.3389/fcvm.2022.979631.
27. Alvarez-Cardona JA, Ray J, Carver J, Zaha V, Cheng R, Yang E, et al. Cardio-Oncology Education and Training. J Am Coll Cardiol [Internet]. 2020 Nov;76(19):2267-81. https://doi.org/10.1016/j.jacc.2020.08.079.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mustafa H. Ajlan, Hasan A. Farhan, Zainab A. Dakhil
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution 4.0 International license..
